Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Mary Y Wu; Scott T C Shepherd; Annika Fendler; Edward J Carr; Lewis Au; Ruth Harvey; Giulia Dowgier; Agnieszka Hobbs; Lou S Herman; Martina Ragno; Lorin Adams; Andreas M Schmitt; Zayd Tippu; Benjamin Shum; Sheima Farag; Aljosja Rogiers; Nicola O'Reilly; Philip Bawumia; Callie Smith; Eleanor Carlyle; Kim Edmonds; Lyra Del Rosario; Karla Lingard; Mary Mangwende; Lucy Holt; Hamid Ahmod; Justine Korteweg; Tara Foley; Taja Barber; Stephanie Hepworth; Andrea Emslie-Henry; Niamh Caulfield-Lynch; Fiona Byrne; Daqi Deng; Bryan Williams; Michael Brown; Simon Caidan; Mike Gavrielides; James I MacRae; Gavin Kelly; Kema Peat; Denise Kelly; Aida Murra; Kayleigh Kelly; Molly O'Flaherty; Sanjay Popat; Nadia Yousaf; Shaman Jhanji; Kate Tatham; David Cunningham; Nicholas Van As; Kate Young; Andrew J S Furness; Lisa Pickering; Rupert Beale; Charles Swanton; Sonia Gandhi; Steve Gamblin; David L V Bauer; George Kassiotis; Michael Howell; Susanna Walker; Emma Nicholson; James Larkin; Emma C Wall; Samra Turajlic; CAPTURE consortium

doi:10.1016/j.ccell.2023.04.005

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Cancer Cell. 2023 May 8;41(5):821-823. doi: 10.1016/j.ccell.2023.04.005. Epub 2023 Apr 13.

Authors

Mary Y Wu¹, Scott T C Shepherd², Annika Fendler³, Edward J Carr⁴, Lewis Au⁵, Ruth Harvey⁶, Giulia Dowgier¹, Agnieszka Hobbs¹, Lou S Herman¹, Martina Ragno¹, Lorin Adams⁶, Andreas M Schmitt⁷, Zayd Tippu², Benjamin Shum², Sheima Farag⁷, Aljosja Rogiers⁷, Nicola O'Reilly⁶, Philip Bawumia⁸, Callie Smith⁸, Eleanor Carlyle⁷, Kim Edmonds⁷, Lyra Del Rosario⁷, Karla Lingard⁷, Mary Mangwende⁷, Lucy Holt⁷, Hamid Ahmod⁷, Justine Korteweg⁷, Tara Foley⁷, Taja Barber⁹, Stephanie Hepworth⁹, Andrea Emslie-Henry⁹, Niamh Caulfield-Lynch⁹, Fiona Byrne⁹, Daqi Deng⁹, Bryan Williams¹⁰, Michael Brown¹¹, Simon Caidan¹², Mike Gavrielides¹³, James I MacRae¹⁴, Gavin Kelly¹⁵, Kema Peat⁷, Denise Kelly⁷, Aida Murra⁷, Kayleigh Kelly⁷, Molly O'Flaherty⁷, Sanjay Popat¹⁶, Nadia Yousaf¹⁷, Shaman Jhanji¹⁸, Kate Tatham¹⁸, David Cunningham¹⁹, Nicholas Van As²⁰, Kate Young⁷, Andrew J S Furness²¹, Lisa Pickering⁷, Rupert Beale⁴, Charles Swanton²², Sonia Gandhi²³, Steve Gamblin²⁴, David L V Bauer²⁵, George Kassiotis²⁶, Michael Howell²⁷, Susanna Walker¹⁸, Emma Nicholson²⁸, James Larkin²¹, Emma C Wall²⁹, Samra Turajlic³⁰; CAPTURE consortium

Affiliations

¹ COVID Surveillance Unit, The Francis Crick Institute, London NW1 1AT, UK.
² Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
³ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
⁴ Cell Biology of Infection Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Division of Medicine, University College London, London NW1 2PG, UK.
⁵ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK; Department of Medical Oncology, Peter MacCallum Cancer Centre, VIC 3010, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Melbourne, Australia.
⁶ Worldwide Influenza Centre, The Francis Crick Institute, London NW1 1AT, UK.
⁷ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
⁸ Human Biology Science and Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
⁹ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
¹⁰ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK.
¹¹ University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London WC1E 6BT, UK; Clinical Research Department, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
¹² Safety, Health & Sustainability, The Francis Crick Institute, London NW1 1AT, UK.
¹³ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁴ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London NW1 1AT, UK.
¹⁵ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁶ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁷ Lung Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁸ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
¹⁹ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, SM2 5PT, UK.
²⁰ Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London NW1 1AT, UK.
²¹ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK.
²² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London NW1 1AT, UK; University College London Cancer Institute, London WC1E 6DD, UK.
²³ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK; UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
²⁴ Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁵ RNA Virus Replication Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁶ Retroviral Immunology Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁷ High Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
²⁸ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Haemato-oncology Unit, The Institute of Cancer Research, London SW7 3RP, UK.
²⁹ School of Life and Medical Sciences, University College London, 235 Euston Road, London NW1 2BU, UK; The Francis Crick Institute, London NW1 1AT, UK. Electronic address: emma.wall@crick.ac.uk.
³⁰ Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.

Abstract

Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Hematologic Neoplasms* / drug therapy
Humans
Neoplasms*
SARS-CoV-2

Substances

sotrovimab

Abstract

Publication types

MeSH terms

Substances

Grants and funding